2 Investors with a high level of short interests are watching News ad

Short sales is an interesting part of the stock market, which can be dangerous and even controversial. Investors selling shares are short, hopes that the price of certain shares falls so that they can make a profit.

Short compression are examples of how short sales can be mistaken for those who take part. However, short sales play a key role in the healthy market. This allows bear investors to balance the potential excess operation of others.

A short percentage of percentage of shares in circulation is the key to fighting bear mood. He measures the total percentage of suitable shares of the company that is currently sold. A higher number indicates a large rate for a drop in shares.

Below I will tell you in detail about the two known shares that have among the largest interest interest on the market. I will explain why some investors are so pessimistic against these companies and provide counterarguments where it is necessary.

Nuscale is the first to reach the NRC SMR Design certification

Nuscale Power NYSE: SMR It is a high -ranking action with a large percentage of 21%. The company’s shares have reached an incredible profit of 610% over the past 52 weeks as of the closure of February 24. Despite the fact that over the past 12 months, the revenue brings only $ 7 million, the grown growth of shares has been related to expectations regarding what it can become.

Nuscale produces small nuclear reactors (SMRS). Nuclear energy is the choice of energy for hyper -scale companies striving to ensure that their data centers for promoting the revolution of artificial intelligence.

SMRS can offer a cheaper and faster source of nuclear energy compared to large nuclear reactors that can take ten years. Nevertheless, the economic viability of this technology is still doubtful, which leads to high short interests.

Nuscale, in particular, had to cancel my project to create the first SMR in the United States from the costs of waiting. Nevertheless, Nuscale is the first and only company that received the certification of SMR Design from the US Nuclear Regulation Commission (NRC). He hopes to get permission for another design in mid -2015.

In addition, its SMR is “only the United States, approved by NRC technology with reactors, is already in production.”

His & hes: lack of semaglutides ends, leaving the future vague

Almost 27% of his health NYSE: Hims Promotions are briefly sold, and these sellers recently received exactly what they hoped for. Hims earns a lot of money thanks to its drug strategy, in the market of weight loss.

With insatiable consumer demand for weight loss medications produced by Eli Lilly and the company NYSE: Lly and novo nordisk a/s NYSE: NVOTwo companies could not maintain production high enough.

This led to the fact that the drugs of Tyrzepatide and Semaglutid were in the list of lack of management control controls (FDA). If so, legal exceptions allow other companies to sell these drugs without violating the law.

In May 2024, His began selling complex Semaglutide from a shortage of Novaya.

This allowed the company to increase the revenue by 69% in 2024. However, Novo invested billions in an increase in supply. On February 21, FDA announced that he had removed Semaglutid from his list of lack. Now HIS is no longer allowed to sell its complex version after May 22.

It was an event on which many short sellers made bets. Promotions fell by almost 26% on the same day. On February 24, shares fell by another 18% in non -working hours.

At the moment, it is difficult to offer a lot of counterarguments, what short sellers did. Nevertheless, HIS claims that he can still sell personalized formulations of Semaglutide.

This will include a change in dosage levels and titration graphs. Data on drugs for weight loss in development, Cagisema show that personalizing dosage and titration can bring significant advantages. Nevertheless, His will probably encounter significant legal control if he tries to do this.

The company also saw a significant increase in revenue by 43% with the exclusion of sales from its drug for weight loss. This shows that the company does not completely depend on the sale of drugs for weight loss in order to quickly develop its business.

Even if he cannot sell Semaglutid in the future, his entrance to this space significantly increased the recognition of the brand and number of subscribers. The company can use this to increase sales of other products. Nevertheless, it is probably best to wait until the dust around this reserve now settles.

Before considering Nuscale Power, you will want to hear it.

Marketbeat monitors the highest and most effective analysts with the most effective Wall Street analysts and promotions that they recommend to their customers daily. Marketbeat has identified five shares that leading analysts quietly whisper to their customers to buy now before the wider market wins … and Nuscale Power was not on the list.

While Nuscale Power is currently undergoing a “moderate purchase” rating among analysts, analysts with the highest rating believe that these five promotions are better buying.

View five shares here

Like this article? Share this with a colleague.

The link is copied to the exchange buffer.